No significant strengths identified
| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| KPRXKiora Pharmaceuticals, Inc. | 8.05M | 2.19 | 2.52 | 22.47% | -38.12% | 100% | 0.00 | |
| KALAKALA BIO, Inc. | 16.74M | 0.60 | -0.09 | -141.11% | -388.29% | 2.62 | ||
| CLSDClearside Biomedical, Inc. | 5.81M | 1.11 | -0.16 | -79.77% | -7.81% | |||
| OTLKOutlook Therapeutics, Inc. | 33.47M | 0.52 | -0.29 | -25.93% | ||||
| ADVMAdverum Biotechnologies, Inc. | 96.26M | 4.36 | -0.66 | -72.22% | -130.93% | -189.84% | 1.30 | |
| IRDOpus Genetics, Inc. | 143.45M | 2.08 | -0.97 | -42.3% | -466.09% | -11.43% | ||
| SKYESkye Bioscience, Inc. | 30.87M | 0.96 | -1.32 | -156.01% | 0.01 | |||
| ALDXAldeyra Therapeutics, Inc. | 265.32M | 4.41 | -4.69 | -87.71% | 0.22 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 250.65M | 66.56M | 75.42M | 396.59M | 781.37M |
| Revenue Growth % | - | - | - | - | - | - | -0.73% | 0.13% | 4.26% | 0.97% |
| Cost of Goods Sold | 0 | 0 | 0 | 127.92M | 595.45K | 25.05M | 5.2M | 5.64M | 58.51M | 117.72M |
| COGS % of Revenue | - | - | - | - | - | 0.1% | 0.08% | 0.07% | 0.15% | 0.15% |
| Gross Profit | 0 | 0 | -50.77M | -127.92M | -595.45K | 225.6M | 61.36M | 69.79M | 338.08M | 663.64M |
| Gross Margin % | - | - | - | - | - | 0.9% | 0.92% | 0.93% | 0.85% | 0.85% |
| Gross Profit Growth % | - | - | - | -1.52% | 1% | 379.87% | -0.73% | 0.14% | 3.84% | 0.96% |
| Operating Expenses | 20.09M | 27.28M | 50.77M | 127.92M | 287.42M | 439.32M | 597.64M | 664.4M | 855.2M | 828.62M |
| OpEx % of Revenue | - | - | - | - | - | 1.75% | 8.98% | 8.81% | 2.16% | 1.06% |
| Selling, General & Admin | 6.36M | 4.3M | 10.46M | 22.64M | 66.45M | 139.4M | 176.77M | 277.16M | 500.81M | 501.05M |
| SG&A % of Revenue | - | - | - | - | - | 0.56% | 2.66% | 3.67% | 1.26% | 0.64% |
| Research & Development | 13.73M | 22.98M | 40.3M | 105.29M | 220.97M | 299.92M | 420.87M | 387.24M | 354.39M | 327.57M |
| R&D % of Revenue | - | - | - | - | - | 1.2% | 6.32% | 5.13% | 0.89% | 0.42% |
| Other Operating Expenses | 6.28K | 157.71K | 11.54K | -111K | 0 | -501K | 1.36M | -288K | 0 | 0 |
| Operating Income | -46.57M | -27.28M | -50.77M | -127.92M | -288.02M | -213.73M | -536.28M | -594.61M | -517.12M | -164.98M |
| Operating Margin % | - | - | - | - | - | -0.85% | -8.06% | -7.88% | -1.3% | -0.21% |
| Operating Income Growth % | -3.12% | 0.41% | -0.86% | -1.52% | -1.25% | 0.26% | -1.51% | -0.11% | 0.13% | 0.68% |
| EBITDA | 6.4M | 0 | -50.76M | 0 | -287.42M | -212.87M | -534.78M | -593.13M | -515.42M | -163.18M |
| EBITDA Margin % | - | - | - | - | - | -0.85% | -8.03% | -7.86% | -1.3% | -0.21% |
| EBITDA Growth % | 1.57% | -1% | - | 1% | - | 0.26% | -1.51% | -0.11% | 0.13% | 0.68% |
| D&A (Non-Cash Add-back) | 52.97M | 27.28M | 11.94K | 127.92M | 595.45K | 859K | 1.49M | 1.49M | 1.7M | 1.8M |
| EBIT | -46.52M | -27.13M | -50.91M | -124.99M | -299.42M | -313.09M | -732.76M | -618.88M | -496.92M | -156.32M |
| Net Interest Income | 0 | 0 | -96.92K | 447.81K | -176K | -25.77M | -12.82M | -23.71M | -8.65M | -27.62M |
| Interest Income | 0 | 0 | 0 | 2.96M | 5.11M | 4.16M | 418K | 8.91M | 20.93M | 12.77M |
| Interest Expense | 0 | 0 | 96.92K | 2.51M | 5.29M | 29.94M | 13.24M | 32.63M | 29.58M | 40.39M |
| Other Income/Expense | 57.14K | 157.71K | -239K | 422.81K | -16.69M | -129.3M | -209.72M | -56.89M | -9.38M | -31.74M |
| Pretax Income | -46.52M | -27.13M | -51.01M | -127.5M | -304.71M | -343.03M | -746M | -651.5M | -526.5M | -196.72M |
| Pretax Margin % | - | - | - | - | - | -1.37% | -11.21% | -8.64% | -1.33% | -0.25% |
| Income Tax | 0 | 0 | 250.61K | -533K | 0 | 1.84M | 352K | 669K | 2.13M | 1.16M |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 1% | 1.01% | 1% | 1% | 1% | 1.01% |
| Net Income | -46.52M | -27.13M | -51.01M | -127.5M | -304.71M | -344.87M | -746.35M | -652.17M | -528.63M | -197.88M |
| Net Margin % | - | - | - | - | - | -1.38% | -11.21% | -8.65% | -1.33% | -0.25% |
| Net Income Growth % | -3.31% | 0.42% | -0.88% | -1.5% | -1.39% | -0.13% | -1.16% | 0.13% | 0.19% | 0.63% |
| Net Income (Continuing) | -46.52M | -27.13M | -51.01M | -127.5M | -304.71M | -344.87M | -746.35M | -652.17M | -528.63M | -197.88M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -2.57 | -1.50 | -1.49 | -2.34 | -4.98 | -4.59 | -8.84 | -6.15 | -4.45 | -1.60 |
| EPS Growth % | -3.28% | 0.42% | 0.01% | -0.57% | -1.13% | 0.08% | -0.93% | 0.3% | 0.28% | 0.64% |
| EPS (Basic) | -2.57 | -1.50 | -1.49 | -2.34 | -4.98 | -4.59 | -8.84 | -6.15 | -4.45 | -1.60 |
| Diluted Shares Outstanding | 18.09M | 18.09M | 34.22M | 54.4M | 62.23M | 75.16M | 84.42M | 106.11M | 118.68M | 123.91M |
| Basic Shares Outstanding | 18.09M | 18.09M | 34.22M | 54.4M | 62.23M | 75.16M | 84.42M | 106.11M | 118.68M | 123.91M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 38.04M | 27.37M | 182.02M | 202.44M | 373.09M | 917.19M | 824.05M | 719.52M | 766.33M | 788.95M |
| Cash & Short-Term Investments | 36M | 24.86M | 175.64M | 176.27M | 351.99M | 877.65M | 701.23M | 551.8M | 352.3M | 416.14M |
| Cash Only | 36M | 24.86M | 175.64M | 176.27M | 351.99M | 565.78M | 640.19M | 551.8M | 351.19M | 411.29M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 311.87M | 61.03M | 0 | 1.11M | 4.85M |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 25M | 80.1M | 7.73M | 206.44M | 271.72M |
| Days Sales Outstanding | - | - | - | - | - | 36.41 | 439.25 | 37.39 | 190 | 126.93 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 24M | 85.71M | 146.36M | 82.48M |
| Days Inventory Outstanding | - | - | - | - | - | - | 1.68K | 5.55K | 913.04 | 255.74 |
| Other Current Assets | 2.04M | 1.37M | 1.31M | 1.84M | 1.31M | 11.14M | 13.54M | 36.66M | 22.41M | 9.1M |
| Total Non-Current Assets | 133.27K | 64.53K | 116.15K | 1.09M | 16.15M | 43.38M | 57.72M | 40.69M | 22.4M | 96.1M |
| Property, Plant & Equipment | 0 | 0 | 0 | 977.92K | 15.77M | 24.52M | 26.08M | 24.89M | 21.09M | 19.04M |
| Fixed Asset Turnover | - | - | - | - | - | 10.22x | 2.55x | 3.03x | 18.80x | 41.05x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.24M | 0 |
| Other Non-Current Assets | 133.27K | 64.53K | 116.15K | 116.42K | 385.09K | 18.86M | 31.64M | 15.8M | -1.93M | 77.06M |
| Total Assets | 38.18M | 27.43M | 182.13M | 203.53M | 389.24M | 960.57M | 881.76M | 760.22M | 788.73M | 885.05M |
| Asset Turnover | - | - | - | - | - | 0.26x | 0.08x | 0.10x | 0.50x | 0.88x |
| Asset Growth % | 1.67% | -0.28% | 5.64% | 0.12% | 0.91% | 1.47% | -0.08% | -0.14% | 0.04% | 0.12% |
| Total Current Liabilities | 3.2M | 3.64M | 6.55M | 17.02M | 65.75M | 128.33M | 131.85M | 167.61M | 247.59M | 185.51M |
| Accounts Payable | 2.48M | 2.55M | 3.66M | 10.25M | 8.36M | 8.48M | 16.91M | 37.34M | 37.52M | 38.57M |
| Days Payables Outstanding | - | - | - | 29.26 | 5.12K | 123.52 | 1.19K | 2.42K | 234.03 | 119.59 |
| Short-Term Debt | 0 | 0 | 0 | 1.67M | 2.61M | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 43.34M | 4.23M | 7.58M | 81.43M | 75.83M | 0 |
| Current Ratio | 11.89x | 7.52x | 27.77x | 11.89x | 5.67x | 7.15x | 6.25x | 4.29x | 3.10x | 4.25x |
| Quick Ratio | 11.89x | 7.52x | 27.77x | 11.89x | 5.67x | 7.15x | 6.07x | 3.78x | 2.50x | 3.81x |
| Cash Conversion Cycle | - | - | - | - | - | - | 937.19 | 3.17K | 869.01 | 263.08 |
| Total Non-Current Liabilities | 0 | 0 | 26.63M | 25.54M | 289.26M | 627.68M | 551.26M | 422.74M | 346.62M | 471M |
| Long-Term Debt | 0 | 0 | 26.39M | 25.38M | 142.57M | 358.83M | 189.02M | 92.74M | 93.03M | 452.83M |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 11.86M | 15.22M | 17.08M | 14.35M | 11.45M | 10.2M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 244.29K | 158.78K | 134.84M | 253.64M | 345.15M | 315.65M | 242.13M | 7.97M |
| Total Liabilities | 3.2M | 3.64M | 33.19M | 42.56M | 355.02M | 756.01M | 683.1M | 590.35M | 594.21M | 656.51M |
| Total Debt | 0 | 0 | 26.39M | 27.04M | 157.03M | 377.73M | 210.22M | 112.71M | 110.93M | 469.78M |
| Net Debt | -36M | -24.86M | -149.25M | -149.22M | -194.95M | -188.05M | -429.97M | -439.09M | -240.26M | 58.49M |
| Debt / Equity | - | - | 0.18x | 0.17x | 4.59x | 1.85x | 1.06x | 0.66x | 0.57x | 2.06x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | -5.63x | - | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | -523.83x | -50.91x | -54.50x | -7.14x | -40.50x | -18.23x | -17.48x | -4.08x |
| Total Equity | 34.98M | 23.79M | 148.94M | 160.97M | 34.23M | 204.56M | 198.66M | 169.87M | 194.52M | 228.54M |
| Equity Growth % | 1.64% | -0.32% | 5.26% | 0.08% | -0.79% | 4.98% | -0.03% | -0.14% | 0.15% | 0.17% |
| Book Value per Share | 1.93 | 1.32 | 4.35 | 2.96 | 0.55 | 2.72 | 2.35 | 1.60 | 1.64 | 1.84 |
| Total Shareholders' Equity | 34.98M | 23.79M | 148.94M | 160.97M | 34.23M | 204.56M | 198.66M | 169.87M | 194.52M | 228.54M |
| Common Stock | 843 | 843 | 5.03K | 5.63K | 6.39K | 8K | 10K | 11K | 12K | 12K |
| Retained Earnings | -71.13M | -98.26M | -149.26M | -276.77M | -581.47M | -926.35M | -1.66B | -2.31B | -2.84B | -3.04B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | -122.81K | -153.78K | -117K | -2.09M | -875K | -3.54M | -3.31M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -18.86M | -26M | -46.6M | -131.24M | -211.13M | -160.49M | -563.13M | -513.75M | -594.74M | -87.87M |
| Operating CF Margin % | - | - | - | - | - | -0.64% | -8.46% | -6.81% | -1.5% | -0.11% |
| Operating CF Growth % | -0.9% | -0.38% | -0.79% | -1.82% | -0.61% | 0.24% | -2.51% | 0.09% | -0.16% | 0.85% |
| Net Income | -46.52M | -27.12M | -51.01M | -127.5M | -304.71M | -344.87M | -746.35M | -652.17M | -528.63M | -197.88M |
| Depreciation & Amortization | 0 | 0 | 11.94K | 0 | 596K | 859K | 1.49M | 1.49M | 1.7M | 1.8M |
| Stock-Based Compensation | 545.7K | 1.08M | 5.42M | 7.73M | 21.14M | 45.38M | 70.67M | 91.08M | 105.94M | 114.13M |
| Deferred Taxes | 0 | 0 | 153.69K | 0 | 0 | 0 | 198.26M | 0 | 0 | 0 |
| Other Non-Cash Items | 26.49M | 1.01M | 13.56K | 568.33K | 18.52M | 118.56M | 6.33M | 61.55M | 26.41M | 12.44M |
| Working Capital Changes | 628.31K | 42.57K | -1.19M | -12.04M | 53.31M | 19.59M | -93.52M | -15.7M | -200.17M | -18.36M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | -10.1M | 2.38M | 0 | -58.48M |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | -16.32M | -69.4M | 0 | -10.76M |
| Change in Payables | 1.73M | 69.78K | 932.3K | 6.59M | -1.64M | -54K | 10.49M | 18.69M | 170K | 1.09M |
| Cash from Investing | 0 | 0 | 0 | 0 | -1.69M | -316.99M | 247.62M | 59.89M | -674K | -403K |
| Capital Expenditures | 0 | 0 | 0 | 0 | -1.69M | -5.42M | -1.1M | -1.52M | -773K | -403K |
| CapEx % of Revenue | - | - | - | - | - | 0.02% | 0.02% | 0.02% | 0% | 0% |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 248.72M | 61.42M | 99K | 0 |
| Cash from Financing | 41.24M | 14.86M | 197.38M | 131.9M | 388.54M | 692.18M | 392.24M | 365.66M | 394.5M | 149.24M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | -90.87K | 0 | 1.2M | 709.36K | 94.75M | -12.12M | 11.87M | -14.46M | 10.11M | -235.04M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -18.86M | -26M | -46.6M | -131.24M | -212.83M | -165.91M | -564.23M | -515.27M | -595.51M | -88.27M |
| FCF Margin % | - | - | - | - | - | -0.66% | -8.48% | -6.83% | -1.5% | -0.11% |
| FCF Growth % | -0.89% | -0.38% | -0.79% | -1.82% | -0.62% | 0.22% | -2.4% | 0.09% | -0.16% | 0.85% |
| FCF per Share | -1.04 | -1.44 | -1.36 | -2.41 | -3.42 | -2.21 | -6.68 | -4.86 | -5.02 | -0.71 |
| FCF Conversion (FCF/Net Income) | 0.41x | 0.96x | 0.91x | 1.03x | 0.69x | 0.47x | 0.75x | 0.79x | 1.13x | 0.44x |
| Interest Paid | 0 | 0 | 0 | 0 | 987K | 12.93M | 10.27M | 5M | 0 | 29.37M |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 49K | 4.92M | 0 | 1.65M |
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -193.01% | -92.31% | -59.06% | -82.28% | -312.2% | -288.86% | -370.2% | -353.93% | -290.14% | -93.55% |
| Return on Invested Capital (ROIC) | - | - | - | -1677.51% | - | -970.89% | - | - | - | -102.56% |
| Gross Margin | - | - | - | - | - | 90.01% | 92.19% | 92.53% | 85.25% | 84.93% |
| Net Margin | - | - | - | - | - | -137.59% | -1121.27% | -864.7% | -133.29% | -25.32% |
| Debt / Equity | - | - | 0.18x | 0.17x | 4.59x | 1.85x | 1.06x | 0.66x | 0.57x | 2.06x |
| Interest Coverage | - | - | -523.83x | -50.91x | -54.50x | -7.14x | -40.50x | -18.23x | -17.48x | -4.08x |
| FCF Conversion | 0.41x | 0.96x | 0.91x | 1.03x | 0.69x | 0.47x | 0.75x | 0.79x | 1.13x | 0.44x |
| Revenue Growth | - | - | - | - | - | - | -73.44% | 13.31% | 425.83% | 97.02% |
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Product | - | 15.15M | 65.09M | 366.28M | 709.95M |
| Product Growth | - | - | 329.74% | 462.71% | 93.83% |
| Licensing And Other Revenue | - | 51.42M | 10.33M | 30.31M | 71.41M |
| Licensing And Other Revenue Growth | - | - | -79.91% | 193.42% | 135.61% |
| Collaboration | 152K | - | - | - | - |
| Collaboration Growth | - | - | - | - | - |
Apellis Pharmaceuticals, Inc. (APLS) reported $1.02B in revenue for fiscal year 2024.
Apellis Pharmaceuticals, Inc. (APLS) grew revenue by 97.0% over the past year. This is strong growth.
Yes, Apellis Pharmaceuticals, Inc. (APLS) is profitable, generating $45.0M in net income for fiscal year 2024 (-25.3% net margin).
Apellis Pharmaceuticals, Inc. (APLS) has a return on equity (ROE) of -93.5%. Negative ROE indicates the company is unprofitable.
Apellis Pharmaceuticals, Inc. (APLS) generated $78.6M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.